Genova Burns Aids New Jersey Based Pharmaceutical Manufacturer in Challenging Chapter 11 Process

Genova Burns Partners Daniel M. Stolz and Don W. Clarke recently helped InvaTech Pharma Solutions LLC, a New Jersey–based generic pharmaceutical manufacturer, navigate a challenging Chapter 11 process and reach a successful outcome. InvaTech operated an FDA registered manufacturing facility and produced a wide range of generic prescription products, including treatments for cardiovascular, gastrointestinal, dermatological, respiratory, and ophthalmic conditions, supported by a robust pipeline of approved and pending ANDAs. Through careful planning and execution, the team secured Bankruptcy Court approval for an asset sale valued just under $3 million.

After a thorough and competitive Section 363 sale process that attracted interest from buyers around the globe, the U.S. Bankruptcy Court for the District of New Jersey approved the sale of substantially all of InvaTech’s assets free and clear of all liens and claims to Advagen Holdings, Inc., a subsidiary of Rubicon Research Limited. The transaction preserved the value of a highly regulated pharmaceutical operation, allowed FDA compliant manufacturing to continue without disruption, and provided clarity and momentum for creditors and other stakeholders.

With the support of Counsel Susan A. Long and Associate R. Edward Stone, this outcome reflects Genova Burns’ hands on experience in restructuring, bankruptcy M&A, and transactions in heavily regulated industries. From crafting value driven bidding procedures to negotiating the stalking horse transaction and advocating for approval in court, the team is proud to have delivered a strong, market driven result at a pivotal moment for InvaTech and those invested in its future.